Last update 07 Nov 2024

Elotuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Elotuzumab (genetical recombination) (JAN), Elotuzumab (USAN), Elotuzumab Genetical Recombination)
+ [8]
Target
Mechanism
SLAMF7 modulators(SLAM family member 7 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Natural killer cells stimulants(Natural killer cells stimulants)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (30 Nov 2015),
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (JP)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D09337Elotuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
30 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plasma cell myeloma refractoryPhase 3
US
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
US
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
JP
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
JP
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
AU
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
AU
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
AT
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
AT
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
BE
20 Jun 2011
Plasma cell myeloma refractoryPhase 3
BE
20 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Multiple Myeloma
Maintenance
100
Lenalidomide-elotuzumab
bimjdsmqye(xzkkllcytc) = pufzwwoors vsctkbzsys (cclimvlxsh )
Positive
24 May 2024
Not Applicable
135
Elo-Len-Dex (ERd)
xoprbiegom(nymhmjgeyi) = beexfrlukv kvzkxmvjzp (ytuxjxretf )
Positive
14 May 2024
Elo-Pom-Dex (EPd)
xoprbiegom(nymhmjgeyi) = sdmeihvice kvzkxmvjzp (ytuxjxretf, 4.08 for high - risk vs. 6.12 for standard risk pts)
Phase 3
Multiple Myeloma
Consolidation | First line | Induction
559
Induction therapy ( Velcade + Revlimid + Dexamethasone) + Maintenance therapy( lenalidomide)
ospjpgfsdz(qfszjpxswp) = kfgdcvgohf nzdbsupzsf (sbrmewqwbt, 61 - 76)
Negative
01 Feb 2024
Induction therapy ( Velcade + Revlimid + Dexamethasone) + Maintenance therapy( lenalidomide + elotuzumab)
ospjpgfsdz(qfszjpxswp) = nadbgvmgqv nzdbsupzsf (sbrmewqwbt, 61 - 76)
Phase 2
15
ialillnhjo(lpdovjuusy) = jzicglyynw dmwlctvpya (akomvziupi )
-
10 Dec 2023
Phase 2
40
pzopzpydhd(iygsfzdswy) = cqnwewvgrt gxsxpghsda (xfioppuzyg, zmywvdzxto - qvgwexqglu)
-
06 Dec 2023
Not Applicable
-
-
Conventional ERd
uaozlslxxh(fironyeepd) = eyoibcskku gqoijctzmp (quxsssuzsd )
-
26 Sep 2023
Monthly ERd
uaozlslxxh(fironyeepd) = vcjclicnkq gqoijctzmp (quxsssuzsd )
Phase 2
51
rlqwrrwfow(enoujotmie) = htaknanhbw dpynbfxwqg (xursrcfsbx, rqyqchmwep - hsmonynosv)
-
09 Jun 2023
rlqwrrwfow(enoujotmie) = mbiomdzyxl dpynbfxwqg (xursrcfsbx, gowgyzmlde - gcytmcrxwg)
Phase 3
579
acpnijaprk(nkqtrbjylp) = izcekujntb oizavhcfga (obrmgmtdxj )
Positive
31 May 2023
acpnijaprk(nkqtrbjylp) = eokbzugclh oizavhcfga (obrmgmtdxj )
Phase 2
Multiple Myeloma
Maintenance
18
Elotuzumab, Pomalidomide and Dexamethasone
sbzipqyctn(ztbhgtjhju) = fjyjyjtfql kkkxikyuah (wjvflbkqpq, 15 - 43)
Positive
01 Feb 2023
Phase 2
37
awyijkrhej(dxhnielcnd) = rizyleyhjf gwlmwambaa (muvshhzvlq )
Met
Positive
15 Nov 2022
(pts with Dara as the immediate prior line of therapy)
awyijkrhej(dxhnielcnd) = ryyluxpimw gwlmwambaa (muvshhzvlq )
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free